isaralgagene civaparvovec

Gene therapy / editing

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

Company guidance: regulatory filing expected Q4 2026 (PTC Therapeutics, 29 Oct 2026). “Acquired ST-920 Fabry disease gene therapy; BLA submission expected to be completed in Q4 2026 –” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Fabry Disease

Competitive landscape

3 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for Fabry Disease: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Isaralgagene Civaparvovec: this drugPhase 1/2Gene therapy / editingAlpha-galactosidase A (GLA / α-Gal A)not yet gradedNo reviewed efficacy summary in this indication
Agalsidase Beta (Fabrazyme)ApprovedProtein / enzyme therapeuticAlpha-galactosidase A (GLA / α-Gal A)Weak signal
NCT00701415: Participants with zero skin GL-3 score: 75% vs 80% at week 52, 56.3% vs 80% at week 156, and 68.8% vs 66.7% at week 260 (0.5 mg/kg every 2 weeks vs 1.0 mg/kg every 4 weeks).
NCT00196716: Open-label low-dose-maintenance study, 21 adult Fabry males (matches registry enrollment_count 21): kidney interstitial capillary endothelial GL-3 clearance (primary endpoint) achieved in 100% of patients during the 1.0mg/kg/2wk standard-dose phase and maintained in 90% after switching to the 0.3mg/kg/2wk low-dose maintenance phase.
Migalastat (Galafold)ApprovedSmall moleculeAlpha-galactosidase A (GLA / α-Gal A)Partial signal
NCT00925301: Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants missed
Pegunigalsidase AlfaApprovedProtein / enzyme therapeuticAlpha-galactosidase A (GLA / α-Gal A)Weak signal
NCT02795676: Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505)

Upcoming events

No upcoming readouts on record for this asset.